Warner Chilcott acquires U.S. rights to bladder drug

Warner Chilcott plc (NASDAQ:WCRX) acquired sole rights in the U.S. to commercialize overactive bladder drug Enablex darifenacin from co-promotion partner Novartis AG (NYSE:NVS; SIX:NOVN). The muscarinic acetylcholine receptor M3 ( CHRM3; HM3) antagonist had 2009 sales in the U.S. of $190 million. Novartis, which retains rights outside the U.S., will receive $400 million up front and up to $20 million in milestones. The deal is expected to close by the end of October. ...